Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)

Boston (September 11, 2024) — Allarity Therapeutics, Inc. (“Allarity” or the “Company”) (NASDAQ: ALLR), a clinical-stage pharmaceutical company dedicated to developing personalized cancer treatments, today announced that the Company is taking a decisive step toward regaining compliance with Nasdaq’s listing requirements, as outlined by the Nasdaq Hearings Panel during a meeting on August 15, 2024. At the meeting, the Nasdaq Hearings Panel approved Allarity’s plan to maintain its listing, contingent upon the ...